Credit Suisse Ag Myovant Sciences Ltd. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$24.03 - $27.02 $4.74 Million - $5.33 Million	197,360 Added 539.0%	233,976 $6.31 Million
Q3 2022 Nov 10, 2022	BUY	$11.6 - $20.44 $89,424 - $157,571	7,709 Added 26.67%	36,616 $657,000
Q2 2022 Aug 12, 2022	BUY	$7.78 - $14.69 $20,173 - $38,091	2,593 Added 9.85%	28,907 $359,000
Q1 2022 May 16, 2022	BUY	$11.38 - $16.4 $18,879 - $27,207	1,659 Added 6.73%	26,314 $350,000
Q4 2021 Feb 14, 2022	SELL	$14.31 - $23.87 $28,433 - $47,429	-1,987 Reduced 7.46%	24,655 $383,000
Q3 2021 Nov 12, 2021	BUY	$18.94 - $26.99 $11,117 - $15,843	587 Added 2.25%	26,642 $598,000
Q2 2021 Aug 16, 2021	SELL	$17.07 - $24.56 $106,431 - $153,131	-6,235 Reduced 19.31%	26,055 $586,000
Q1 2021 May 14, 2021	BUY	$20.46 - $25.18 $97,737 - $120,284	4,777 Added 17.36%	32,290 $664,000
Q4 2020 Feb 12, 2021	SELL	$13.8 - $27.62 $383,446 - $767,449	-27,786 Reduced 50.25%	27,513 $760,000
Q3 2020 Nov 13, 2020	BUY	$14.05 - $22.6 $510,015 - $820,380	36,300 Added 191.06%	55,299 $777,000
Q2 2020 Aug 12, 2020	SELL	$7.34 - $20.84 $80 - $229	-11 Reduced 0.06%	18,999 $392,000
Q1 2020 May 13, 2020	BUY	$6.55 - $14.76 $18,392 - $41,446	2,808 Added 17.33%	19,010 $143,000
Q4 2019 Feb 12, 2020	BUY	$4.2 - $19.21 $5,535 - $25,318	1,318 Added 8.86%	16,202 $251,000
Q3 2019 Nov 12, 2019	BUY	$5.19 - $9.46 $24,621 - $44,878	4,744 Added 46.79%	14,884 $78,000
Q2 2019 Aug 14, 2019	BUY	$8.69 - $25.0 $88,116 - $253,500	10,140 New	10,140 $92,000
Q3 2017 Nov 14, 2017	SELL	$9.93 - $15.47 $131,294 - $204,544	-13,222 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	13,222	13,222 $155,000

Others Institutions Holding MYOV

# of Institutions

Shares Held

61.3K

Call Options Held

Put Options Held

View Full List

About Myovant Sciences Ltd.

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

More about MYOV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account